2018 Left Ventricular Dysfunction Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Left Ventricular Dysfunction Market
Left Ventricular dysfunction can occur as a result of several cardiac disorders. It can either be systolic or diastolic. Further, if the dysfunction is restricted to a small area, it is referred to as coronary artery disease and alternatively if it affects entire ventricle, it is referred to as total left ventricular dysfunction. The disease can occur without any explicit symptoms prior to heart failure.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Left Ventricular Dysfunction pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Left Ventricular Dysfunction pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Left Ventricular Dysfunction pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Left Ventricular Dysfunction pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Left Ventricular Dysfunction pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Left Ventricular Dysfunction pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 LEFT VENTRICULAR DYSFUNCTION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Left Ventricular Dysfunction Pipeline Snapshot
2.3 Left Ventricular Dysfunction Pipeline by Phase
2.4 Left Ventricular Dysfunction Pipeline by Company
2.5 Left Ventricular Dysfunction Pipeline by Mechanism of Action
3 LEFT VENTRICULAR DYSFUNCTION- COMPANY WISE PIPELINE ANALYSIS
Armaron Bio Pty Ltd.
Bayer AG
Innopharmax Inc.
Novartis International AG
Quantum Genomics Corp.
Redhill Biopharma Ltd.
TiGenix NV
4 LEFT VENTRICULAR DYSFUNCTION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN LEFT VENTRICULAR DYSFUNCTION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 LEFT VENTRICULAR DYSFUNCTION PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Left Ventricular Dysfunction Pipeline Snapshot
2.3 Left Ventricular Dysfunction Pipeline by Phase
2.4 Left Ventricular Dysfunction Pipeline by Company
2.5 Left Ventricular Dysfunction Pipeline by Mechanism of Action
3 LEFT VENTRICULAR DYSFUNCTION- COMPANY WISE PIPELINE ANALYSIS
Armaron Bio Pty Ltd.
Bayer AG
Innopharmax Inc.
Novartis International AG
Quantum Genomics Corp.
Redhill Biopharma Ltd.
TiGenix NV
4 LEFT VENTRICULAR DYSFUNCTION R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN LEFT VENTRICULAR DYSFUNCTION PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Left Ventricular Dysfunction Pipeline by Phase, H2- 2018
Figure 2: Left Ventricular Dysfunction Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Left Ventricular Dysfunction Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Left Ventricular Dysfunction Pipeline by Phase, H2- 2018
Figure 2: Left Ventricular Dysfunction Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Left Ventricular Dysfunction Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Left Ventricular Dysfunction Pipeline by Phase, H2- 2018
Left Ventricular Dysfunction Pipeline by Companies, H2- 2018
Left Ventricular Dysfunction Pipeline by Mechanism of Action, H2- 2018
Table 1: Armaron Bio Pty Ltd. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 2: Bayer AG Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 3: Innopharmax Inc. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 4: Novartis International AG Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 5: Quantum Genomics Corp. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 6: Redhill Biopharma Ltd. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 7: TiGenix NV Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Left Ventricular Dysfunction Pipeline by Phase, H2- 2018
Left Ventricular Dysfunction Pipeline by Companies, H2- 2018
Left Ventricular Dysfunction Pipeline by Mechanism of Action, H2- 2018
Table 1: Armaron Bio Pty Ltd. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 2: Bayer AG Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 3: Innopharmax Inc. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 4: Novartis International AG Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 5: Quantum Genomics Corp. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 6: Redhill Biopharma Ltd. Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
Table 7: TiGenix NV Left Ventricular Dysfunction Pipeline Drugs, H2- 2018
